Real-World Gaps, Financial Toxicity, and the Evolving HER2 Treatment Landscape

The widest real-world gap Dr. Wu sees is surveillance adherence. Patients feel well on an oral tyrosine kinase inhibitor (TKI) and struggle to understand why they must return for labs and toxicity checks every 2 weeks during the first 12 weeks of zongertinib, especially when they live 50 miles from clinic like William. When patients are doing well, they may resist in-person visits and even local blood draws. Dr. Wu frames the clinical message clearly: Early liver function test (LFT) elevations are asymptomatic and only detectable through proactive lab monitoring.

Financial toxicity is the second major gap. HER2-directed therapies—trastuzumab deruxtecan (T-DXd) and the oral HER2-selective TKIs—are expensive. Even when National Comprehensive Cancer Network (NCCN)-listed agents are covered, copay structures vary dramatically: $2,000 for the year in one case, an $11,000 deductible in another. Dr. Wu acknowledges that cost sometimes determines drug selection, for instance, using sevabertinib if a patient assistance program makes it accessible when zongertinib is not, even though labeled indications differ (zongertinib first-line; sevabertinib second-line plus).

Looking forward 1–2 years, three phase 3 trials will reshape first-line decision-making: Beamion LUNG-2 (zongertinib), SOHO-02 (sevabertinib), and DESTINY-Lung04 (T-DXd), all versus platinum doublet plus pembrolizumab. Newer oral TKIs and oral antibody-drug conjugates are in development. Central nervous system (CNS) activity data remain immature, and emerging intracranial efficacy data could shift first-line positioning. Combination strategies, mirroring the EGFR-plus-chemotherapy paradigm, are also on the horizon for fit patients seeking maximum disease control.

Dr. Wu closes by synthesizing William's case: first-line decisions in HER2-mutated advanced NSCLC extend beyond the biomarker, integrating tissue adequacy, timing of testing, comorbidities, drug interactions, monitoring needs, transportation barriers, and the patient's confidence that the evidence applies to them.

Thank you for watching this Case-Based Peer Perspectives on first-line management of HER2-mutant NSCLC. Please subscribe to our e-newsletter for information on upcoming video series and continued education in precision oncology.